Defending the mucosa: adjuvant and carrier formulations for mucosal immunity.
about
An Overview of Challenges Limiting the Design of Protective Mucosal Vaccines for FinfishChoice and Design of Adjuvants for Parenteral and Mucosal VaccinesUnlipidated outer membrane protein Omp16 (U-Omp16) from Brucella spp. as nasal adjuvant induces a Th1 immune response and modulates the Th2 allergic response to cow's milk proteinsEnhancement of the immunogenicity and protective efficacy of a mucosal influenza subunit vaccine by the saponin adjuvant GPI-0100.Natural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein.Evaluation of an intranasal virosomal vaccine against respiratory syncytial virus in mice: effect of TLR2 and NOD2 ligands on induction of systemic and mucosal immune responses.Enhancement of Mucosal Immunogenicity of Viral Vectored Vaccines by the NKT Cell Agonist Alpha-Galactosylceramide as Adjuvant.Cytokine production and antigen recognition by human mucosal homing conjunctival effector memory CD8+ T cellsVACCINES. A mucosal vaccine against Chlamydia trachomatis generates two waves of protective memory T cells.Preliminary evidence that the novel host-derived immunostimulant EP67 can act as a mucosal adjuvant.Mucosal vaccine adjuvants update.Parenteral Vaccination Can Be an Effective Means of Inducing Protective Mucosal ResponsesMucosal vaccines: novel strategies and applications for the control of pathogens and tumors at mucosal sites.Protective efficacy by various doses of Salmonella ghost vaccine candidate carrying enterotoxigenic Escherichia coli fimbrial antigen against neonatal piglet colibacillosis.The microbiome and asthma.Acellular vaccines for ovine brucellosis: a safer alternative against a worldwide disease.Mucosal vaccines to prevent porcine reproductive and respiratory syndrome: a new perspective.Recent progress towards development of a Shigella vaccine.Strategies for improving mucosal drug delivery.Adjuvants and delivery systems for antifungal vaccines: current state and future developments.An overview of tuberculosis plant-derived vaccines.Nanocarriers: a versatile approach for mucosal vaccine delivery.Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies.PapMV nanoparticles improve mucosal immune responses to the trivalent inactivated flu vaccine.Recent developments in nanocarrier-aided mucosal vaccination.Induction of mucosal immune responses against Helicobacter pylori infection after sublingual and intragastric route of immunization.Mucosal and systemic immune responses induced by a single time vaccination strategy in mice.Development of enhanced antibody response toward dual delivery of nano-adjuvant adsorbed human Enterovirus-71 vaccine encapsulated carrier.Polysaccharide-protein conjugate vaccination induces antibody production but not sustained B-cell memory in the human nasopharyngeal mucosa.The origin of prostate gland-secreted IgA and IgG.Development of a nanogel-based nasal vaccine as a novel antigen delivery system.LTB-Syn: a recombinant immunogen for the development of plant-made vaccines against synucleinopathies.Development of Safe and Non-Self-Immunogenic Mucosal Adjuvant by Recombinant Fusion of Cholera Toxin A1 Subunit with Protein Transduction Domain.The Mucosal Vaccine Adjuvant LT(R192G/L211A) or dmLT
P2860
Q26777943-85C8AA44-37AB-468A-B8F0-D1C01F35E027Q26783488-8A3C4FF0-A6F4-46EF-A9C4-1D9CAEBE1DC5Q27311087-468C1A65-24CD-4F0F-BD58-8D15EDA994A4Q34533085-DCFFD795-C16B-4860-9AC7-8519801BC7BFQ34625185-A1231C32-7DDE-42B6-BB06-5DFD7C267FB5Q34674831-1CB1CDD2-F7F1-44C3-BC9E-306A88215C2EQ34781602-0B4D0E4B-BFC4-4B02-9759-152EDC37DE70Q34789732-1E56E784-B514-4DAC-A403-D206268FB80DQ36161076-479419D4-1A94-4D23-A4D2-A2ED790D2268Q36315607-ADAD8663-C390-4EF7-BD7D-175290CFECFCQ36758075-EEB7AF35-6ECD-4633-A0C0-D2C2B6C1C4BBQ36973944-DA477B7A-29A5-41E1-B770-D98A969A40F2Q36978334-0F370D22-0C65-4D20-9DE8-3168C12B87DAQ37046073-C9E3C651-D442-41CE-A97A-84A0E205E2B4Q37679762-15BE546F-F7FB-4692-B123-817E20F77B14Q37965725-DED35722-A1D2-4768-ADC4-F74530966D88Q38020309-2056B442-9C96-48E6-80E8-76750FDD8033Q38068954-C2B6C534-B729-4D1F-AB62-BAD9C957F92DQ38166442-21240435-1C60-4223-BF86-2FC66E649299Q38264288-7808CF60-BD83-4FC1-A9E1-2E37771F2C20Q38356275-4A21B617-7789-4789-9B4F-0AC497CF86BCQ38358876-0245CEB7-D029-4E2C-8743-0D856595373BQ38461061-300780D1-02A3-4F0F-A7CE-B4EE3067A068Q39664804-3817DAEA-55CC-42C5-879E-F6F5B6BCFD54Q40228907-79655158-B66E-4763-B961-AB70AEC18F70Q40525875-AEB1C49E-250B-49DB-945A-EFC66879A87FQ41125196-09633F37-12A4-45C1-AC3E-D73E7CF63BC2Q41575418-B4E9E6AE-26A9-4003-A1E7-6149AF5C2DE3Q43876810-C374EF61-1EE0-45CE-8E4E-A35AE053F485Q47138100-E176C6C5-252E-4DB9-A011-F321459F5F6DQ48009563-D1DCBB15-7D31-47E7-AFFC-4E9BD0BF219BQ51094928-1E39E33F-5B56-4FBE-AC45-96898DFBFBFDQ52715734-1F1CC7DA-154F-4BEF-8F46-0234E4FCF429Q57945015-1DA749A9-5535-43CF-BB17-A6C2A39C0981
P2860
Defending the mucosa: adjuvant and carrier formulations for mucosal immunity.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 April 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Defending the mucosa: adjuvant and carrier formulations for mucosal immunity.
@en
Defending the mucosa: adjuvant and carrier formulations for mucosal immunity.
@nl
type
label
Defending the mucosa: adjuvant and carrier formulations for mucosal immunity.
@en
Defending the mucosa: adjuvant and carrier formulations for mucosal immunity.
@nl
prefLabel
Defending the mucosa: adjuvant and carrier formulations for mucosal immunity.
@en
Defending the mucosa: adjuvant and carrier formulations for mucosal immunity.
@nl
P2093
P1476
Defending the mucosa: adjuvant and carrier formulations for mucosal immunity.
@en
P2093
Elizabeth B Norton
John D Clements
Louise B Lawson
P304
P356
10.1016/J.COI.2011.03.009
P577
2011-04-19T00:00:00Z